Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVAH NASDAQ:SGRY NASDAQ:TOI NASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVAHAveanna Healthcare$9.82+2.4%$7.54$3.73▼$10.32$2.14B1.891.53 million shs2.38 million shsSGRYSurgery Partners$16.77+1.6%$14.60$11.41▼$24.10$2.19B1.891.52 million shs1.30 million shsTOIOncology Institute$5.85+3.5%$4.72$2.32▼$6.11$578.21M0.361.91 million shs1.99 million shsVRDNViridian Therapeutics$20.20+1.7%$17.04$13.18▼$34.29$2.08B0.92.29 million shs2.00 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVAHAveanna Healthcare-0.10%+8.24%+44.43%+45.08%+124.07%SGRYSurgery Partners-3.90%-0.60%+19.13%+27.51%-25.88%TOIOncology Institute-2.59%+2.54%+11.44%+81.67%+126.00%VRDNViridian Therapeutics-2.98%+7.47%+26.26%+29.13%+23.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVAHAveanna Healthcare$9.82+2.4%$7.54$3.73▼$10.32$2.14B1.891.53 million shs2.38 million shsSGRYSurgery Partners$16.77+1.6%$14.60$11.41▼$24.10$2.19B1.891.52 million shs1.30 million shsTOIOncology Institute$5.85+3.5%$4.72$2.32▼$6.11$578.21M0.361.91 million shs1.99 million shsVRDNViridian Therapeutics$20.20+1.7%$17.04$13.18▼$34.29$2.08B0.92.29 million shs2.00 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVAHAveanna Healthcare-0.10%+8.24%+44.43%+45.08%+124.07%SGRYSurgery Partners-3.90%-0.60%+19.13%+27.51%-25.88%TOIOncology Institute-2.59%+2.54%+11.44%+81.67%+126.00%VRDNViridian Therapeutics-2.98%+7.47%+26.26%+29.13%+23.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVAHAveanna Healthcare 2.67Moderate Buy$10.567.49% UpsideSGRYSurgery Partners 2.75Moderate Buy$22.1832.27% UpsideTOIOncology Institute 2.67Moderate Buy$8.4043.59% UpsideVRDNViridian Therapeutics 2.86Moderate Buy$38.7992.01% UpsideCurrent Analyst Ratings BreakdownLatest TOI, SGRY, VRDN, and AVAH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2026AVAHAveanna Healthcare BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$9.00 ➝ $9.507/9/2026TOIOncology Institute BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $9.007/6/2026TOIOncology Institute Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.007/2/2026AVAHAveanna Healthcare Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)6/30/2026VRDNViridian Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/30/2026VRDNViridian Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $38.006/30/2026VRDNViridian Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$39.006/30/2026VRDNViridian Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $35.006/30/2026VRDNViridian Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$32.00 ➝ $43.006/29/2026VRDNViridian Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$20.00 ➝ $31.006/29/2026VRDNViridian Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.00(Data available from 7/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVAHAveanna Healthcare$2.43B0.88$0.71 per share13.92$0.93 per share10.56SGRYSurgery Partners$3.31B0.66$1.67 per share10.06$24.21 per share0.69TOIOncology Institute$502.73M1.15N/AN/A($0.16) per share-36.56VRDNViridian Therapeutics$70.92M29.36N/AN/A$6.18 per share3.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVAHAveanna Healthcare$225.03M$1.188.3213.831.0210.37%124.68%7.07%8/6/2026 (Estimated)SGRYSurgery Partners-$77.90M-$0.60N/A47.915.13-2.28%1.04%0.41%8/4/2026 (Estimated)TOIOncology Institute-$60.61M-$0.37N/AN/AN/A-7.42%N/A-24.68%8/12/2026 (Estimated)VRDNViridian Therapeutics-$342.60M-$3.32N/AN/AN/A-490.31%-80.19%-48.84%8/5/2026 (Estimated)Latest TOI, SGRY, VRDN, and AVAH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026AVAHAveanna Healthcare$0.16N/AN/AN/A$637.62 millionN/A8/5/2026Q2 2026VRDNViridian Therapeutics-$1.0229N/AN/AN/A$0.03 millionN/A8/4/2026Q2 2026SGRYSurgery Partners$0.02N/AN/AN/A$830.03 millionN/A5/14/2026Q1 2026AVAHAveanna Healthcare$0.13$0.18+$0.05$0.19$613.22 million$647.92 million5/7/2026Q1 2026TOIOncology Institute-$0.07-$0.02+$0.05-$0.02$142.10 million$147.44 million5/5/2026Q1 2026SGRYSurgery Partners-$0.15-$0.03+$0.12-$0.28$797.69 million$810.90 million5/5/2026Q1 2026VRDNViridian Therapeutics-$1.06-$0.90+$0.16-$0.90$0.04 million$0.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVAHAveanna HealthcareN/AN/AN/AN/AN/ASGRYSurgery PartnersN/AN/AN/AN/AN/ATOIOncology InstituteN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVAHAveanna Healthcare5.351.471.47SGRYSurgery Partners1.171.861.69TOIOncology InstituteN/A1.471.17VRDNViridian Therapeutics0.1015.1515.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVAHAveanna Healthcare87.96%SGRYSurgery PartnersN/ATOIOncology Institute36.86%VRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAVAHAveanna Healthcare5.30%SGRYSurgery Partners2.00%TOIOncology Institute4.40%VRDNViridian Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVAHAveanna Healthcare35,500217.76 million206.21 millionOptionableSGRYSurgery Partners16,000130.79 million128.17 millionOptionableTOIOncology Institute66098.84 million94.49 millionNot OptionableVRDNViridian Therapeutics50103.08 million100.60 millionOptionableTOI, SGRY, VRDN, and AVAH HeadlinesRecent News About These CompaniesWedbush Sees Commercial Edge for Viridian (VRDN) After FDA MilestoneJuly 7 at 3:30 AM | finance.yahoo.comWhich Is a Better Investment, Relay Therapeutics, Inc. or Viridian Therapeutics, Inc. Stock?July 2, 2026 | aaii.comAVRDN Stock Rises 6.3% in a Week: Here's What You Need to KnowJuly 1, 2026 | zacks.comViridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease - SlideshowJuly 1, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Cytokinetics (CYTK)June 30, 2026 | theglobeandmail.comViridian Therapeutics: Lumvoa Ready For Prime Time Following FDA ApprovalJune 30, 2026 | seekingalpha.comViridian secures first FDA approval, sets up challenge to Amgen's Tepezza for thyroid eye diseaseJune 29, 2026 | msn.comViridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease TranscriptJune 29, 2026 | seekingalpha.comViridian launches first commercial product as U.S. approves thyroid eye disease therapyJune 27, 2026 | seekingalpha.comViridian launches first commercial product as US approves thyroid eye disease therapyJune 27, 2026 | msn.comViridian Therapeutics wins FDA nod for Lumvoa for TEDJune 27, 2026 | thepharmaletter.comTVRDN stock jumps 6% after-hours as Viridian wins first FDA approvalJune 27, 2026 | msn.comViridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye DiseaseJune 26, 2026 | businesswire.comViridian’s VRDN-003 Thyroid Eye Disease Trial Reaches Completion, Resetting the Risk/Reward for InvestorsJune 25, 2026 | tipranks.comKopp Family Office LLC Trims Stake in Viridian Therapeutics, Inc. $VRDNJune 25, 2026 | marketbeat.comViridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market AppreciatesJune 25, 2026 | seekingalpha.comPerceptive Advisors LLC Buys 1,580,303 Shares of Viridian Therapeutics, Inc. $VRDNJune 18, 2026 | marketbeat.comViridian Therapeutics, Inc. $VRDN Shares Sold by Eversept Partners LPJune 18, 2026 | marketbeat.comBaker BROS. Advisors LP Grows Stake in Viridian Therapeutics, Inc. $VRDNJune 18, 2026 | marketbeat.com1,500,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Avoro Capital Advisors LLCJune 17, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and Viridian Therapeutics (VRDN)June 12, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTOI, SGRY, VRDN, and AVAH Company DescriptionsAveanna Healthcare NASDAQ:AVAH$9.82 +0.23 (+2.40%) Closing price 04:00 PM EasternExtended Trading$9.82 -0.01 (-0.05%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers PDN services, which include in-home skilled nursing services to medically fragile children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and employer of record support and personal care services, as well as in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.Surgery Partners NASDAQ:SGRY$16.77 +0.27 (+1.64%) Closing price 04:00 PM EasternExtended Trading$16.75 -0.02 (-0.12%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.Oncology Institute NASDAQ:TOI$5.85 +0.20 (+3.54%) Closing price 04:00 PM EasternExtended Trading$5.88 +0.03 (+0.51%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.Viridian Therapeutics NASDAQ:VRDN$20.20 +0.34 (+1.71%) Closing price 04:00 PM EasternExtended Trading$19.93 -0.27 (-1.31%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth Lockheed Martin Secures the Ultimate Defense Moat Why Levi's Digital Strategy Is Paying Off in a Big Way Dollar Tree’s Turnaround Is Starting to Take Root Constellation Brands: Beer Growth and Buybacks Mask Stock's Slump Grounded: SpaceX Stumbles as Grok Fails to Ignite Southwest MAX Incident Revives Headline Risk for Boeing and Airline Stocks Fiserv’s Debit Network Talks Raise a Bigger Question for Visa and Mastercard Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
